ACSL4 and hepatocellular carcinoma: In MASH, the overexpression of ACSL4 leads to enhanced steatosis by inhibiting FAO [117], whereas elevated ACSL4 levels in hepatomas contribute to heightened lipogenesis by indirectly boosting SREBP1 activity [118].